MedTrace Logo

Evaluation of the Pathobiology of CALR-mutated MPN Cells

NCT06480591 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2026-05-22

No results posted yet for this study

Summary

The purpose of this study is to understand why there is a greater risk of thrombosis in patients who have the JAK2 mutation as compared to those with CALR mutations.

Conditions

  • Myeloproliferative Neoplasm

Interventions

OTHER

Blood Draw

The amount of blood that will be collected for this is 50 mL(milliliters), or about 3 ½ tablespoons.

Sponsors & Collaborators

  • Atrium Health Levine Cancer Institute

    collaborator OTHER

  • Brookdale University Hospital Medical Center

    collaborator OTHER

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • Aleksander Chojecki, MD · Atrium Health Levine Cancer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-01-21
Primary Completion
2026-07-31
Completion
2026-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06480591 on ClinicalTrials.gov